Hostname: page-component-77c89778f8-gq7q9 Total loading time: 0 Render date: 2024-07-24T10:01:15.022Z Has data issue: false hasContentIssue false
  • English
  • Français

The Cephalosporin Antibiotic Agents— III. Third-Generation Cephalosporins

Published online by Cambridge University Press:  02 January 2015

T. Donald Marsh
T. Donald Marsh*
Affiliation:
Shenandoah Shared Hospital Services, Inc., Harrisonburg, Virginia
Get access Rights & Permissions [Opens in a new window]

Extract

The third-“generation” cephalosporin antibiotics (Table 1) represent a class of agents with an expanded gram-negative spectrum of activity beyond that of the first- and second-“generation” cephalosporins. Greater stability to beta-lactamases produced by gram-negative organisms confers to these agents a greater bactericidal action against the Enterobacteriaceae. Large bacterial inocula (105/ml) in vitro significantly increase the minimum inhibitory and bactericidal concentrations (MIC and MBC) explaining treatment failures with these agents in infections associated with large numbers of organisms. The pharmacokinetic features of some of the agents allow prolongation of dosing intervals, and enhanced tissue penetration amplifies their clinical utility in infections distant from the bloodstream (eg, meningitis).

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 6 , Issue 2 , February 1985 , pp. 78 - 83
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1985

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Marsh, TD: The cephalosporin antibiotic agents—I. Considered as a group. Infect Control 1984; 5:493–496.Google Scholar
2. Marsh, TD: The cephalosporin antibiotic agents—II. First- and second-generation agents. Infect Control 1984; 5:577–582.CrossRefGoogle ScholarPubMed
3. Benino, JS, Speck, WT: The cephalosporin antibiotics. Pediatr Clin North Am 1983; 30:17–26.Google Scholar
4. Barriere, SL, Flaherty, JF: Third-generation cephalosporins: A critical evaluation. Clin Pharm 1984; 3:351–373.Google ScholarPubMed
5. Sykes, RB, Bush, K: Interaction of new cephalosporins with beta-lactamases and beta-laclamase-producing gram-negative bacilli. Rev Infect Dis 1983; 5(suppl)2:S356–S367.CrossRefGoogle Scholar
6. Neu, HC: Ceftizoxime: A beta-lactamase-stable, broad-spectrum cephalosporin. Pharmacotherapy 1984; 4:47–60.Google Scholar
7. Neu, HC: The new beta-lactamase-stable cephalosporins. Ann Intern Med 1982; 97:408–419.Google Scholar
8. Neu, HC: The in vitro activity, human pharmacology, and clinical effectiveness of new beta-lactam antibiotics. Annu Rev Pharmacol Toxicol 1982; 22:599–642.CrossRefGoogle ScholarPubMed
9. Neu, HC: Structure-activity relations of new beta-lactam compounds and the in vitro activity against common bacteria. Rev Infect Dis 1983; 5(suppl)2:S349–S337.Google Scholar
10. Garzone, P, Lyon, J, Yu, VL: Third-generation and investigational cephalosporins: I. Structure-activity relationships and pharmacokinetic review. Druglntell Clin Pharm 1983; 17:507–515.Google ScholarPubMed
11. Lyon, JA: Cefoperazone (Cefobid, Pfizer). Drug Intell Clin Pharm 1983; 17:7–11.Google ScholarPubMed
12. Fass, RJ: Comparative in vitro activities of third-generation cephalosporins. Arch Intern Med 1983; 143:1743–1745.Google Scholar
13. Jones, RN, Fuchs, PC, Barry, AL, et al: Antimicrobial activity and spectrum of cefoperazone against recent clinical isolates. Clin Ther 1980; 3:14–23.Google ScholarPubMed
14. Garzone, P, Lyon, J, Yu, VL: Third-generation and investigational cephalosporins: II. Microbiologic review and clinical summaries. Drug Intell Clin Pharm 1983; 17:615–622.Google ScholarPubMed
15. Ramirez-Ronda, CH, Nevarez, M, Saavedra, S, et al: Comparative in vitro activity of moxalactam and cefotaxime against isolates from blood culture. JAntimicrob Chemother 1981; 7:629–635.CrossRefGoogle ScholarPubMed
16. Cunha, BA, Ristuccia, AM: Third-generation cephalosporins. Med Clin North Am 1982; 66:283–291.Google Scholar
17. Bayer, AS, Eisenstadt, R, Morrison, JO: Enhanced in vitro bactericidal activity of amikacin or gentamicin combined with three new extended-spectrum cephalosporins against cephalothin-resistant members of the family Enterobacteriaceae . Antimicrob Agents Chemother 1984; 25:725–728.Google Scholar
18. Hooton, TM, Blair, AM Turck, M, et al: Synergism at clinically attainable concentrations of aminoglycoside and beta-lactam antibiotics. Antimicrob Agents Chemother 1984; 26:535–538.Google Scholar
19. Smith, BR: Cefsulodin and ceftazidime, two antipseudomonal cephalosporins. Clin Pharm 1984; 3:373–385.Google ScholarPubMed
20. Godfrey, AJ, Bryan, LE: Resistance of Pseudomonas aeruginosa to new beta-lactamase-resistant beta-lactams. Antimicrob Agents Chemother 1984; 26:485–488.CrossRefGoogle ScholarPubMed
21. Hinkle, AM, LeBlanc, BM, Bodey, GP: In vitro evaluation of cefoperazone. Antimicrob Agents Chemother 1980; 17:423–427.Google Scholar
22. Soriano, F, rbnte, MC, Gaspar, MC: The in vitro responses of Bacteroides fragilis to moxalactam, cefotaxime, cefmetazole, josamycin, and erythromycin. JClin Pathol 1982; 35:1166–1167.CrossRefGoogle ScholarPubMed
23. Kesado, T, Watanabe, K, Asahi, Y, et al: Comparative antibacterial activities of 7-methoxy cephalosporins and 7 -methoxyiminoacetamido cephalosporins against Bacteroides fragilis . Antimicrob Agents Chemother 1984; 25:131–133.Google Scholar
24. Neu, HC: Antibacterial activity of desacetylcefotaxime alone and in combination with cefotaxime. Rev Infect Dis 1982; 4(suppl):S374–S378.Google Scholar
25. Kemmerich, B, Lode, H, Belmega, G, et al: Comparative pharmacokinetics of cefoperazone, cefotaxime, and moxalactam. Antimicrob Agents Chemother 1983; 23:429–434.Google Scholar
26. Giamarellou, H, Gazis, J, Petrikkos, G, et al: A study of cefoxitin, moxalactam, and ceftazidime kinetics in pregnancy. Am J Obstet Gynecol 1983; 147:914–919.CrossRefGoogle ScholarPubMed
27. Landesman, SH, Corrado, ML, Chérubin, CC, et al: Diffusion of a new beta-lactam (LY 127935) into cerebrospinal fluid: Implications for therapy of gram-negative bacillary meningitis. Am J Med 1980; 69:92–98.Google Scholar
28. Noveck, WJ: Levels of cefotaxime in body fruids and tissues: A review. Rev Infect Dis 1982; 4(suppl):S346–535.CrossRefGoogle Scholar
29. Shimada, J, Ueda, Y: Moxalactam-absorpticm, excretion, distribution, and metabolism. Rev Infect Dis 1982; 4(suppl):S569–580.Google Scholar
30. Ti, T, Fortin, L, Kreeft, JH, et al: Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis. Antimicrob Agents Chemother 1984; 25:83–87.CrossRefGoogle ScholarPubMed
31. Fong, IW, Tomkins, KB: Penetration of ceftazidime into the cerebrospinal fluid of patients with and without evidence of meningeal inflammation. Antimicrob Agents Chemother 1984; 26:115–116.Google Scholar
32. Daschner, FD, Metz, B, Spillner, G, et al: Concentrations of cefamandole and cefsulodin in serum, heart valves, subcutaneous tissue, and muscle of patients undergoing open-heart surgery. J Infect Dis 1980; 142:290.Google Scholar
33. Stone, HH, Strom, PR, Fabian, TC, et al: Third-generation cephalosporins for polymicrobial surgical sepsis. Arch Surg 1983; 118:193–200.Google Scholar
34. Foster, TS, Raehl, CL, Wilson, HD: Disulfiram-like reaction associated with a parenteral cephalosporin. Am J Hosp Pharm 1980; 37:858–859.Google ScholarPubMed
35. Olson, DA, Hoeprich, PD, Nolan, SM, et al: Successful treatment of gram-negative bacillary meningitis with moxalactam. Ann Intern Med 1981; 95:302–305.Google Scholar
36. Corrado, ML, Gombert, ME, Cherubin, CE: Designing appropriate therapy in the treatment of gram-negative bacillary meningitis. JAMA 1982; 248:71–74.Google Scholar
37. Harrison, CJ, Welch, D, Marks, MI: Ceftriaxone therapy in pediatric patients. Am J Dis Child 1983; 137:1048–1051.Google Scholar
38. Young, LS: Treatment of respiratory infections in the patient at risk. Am J Med 1984; 76(special issue):61–68.Google Scholar
39. Carmine, AA, Brogden, RN, Heel, RC, et al: Cefotaxime: A review of its antibacterial activity, pharmacological properties and therapeudc use. Drugs 1983; 25:223–289.Google Scholar
40. Smith, CR, Ambinder, R, Lipsky, JJ, et al: Cefotaxime compared with nafcillin plus tobramycin for serious bacterial infections. Ann Intern Med 1984; 101:469–477.Google Scholar
41. Soriano, F, Ponte, MC: Comparative activities of aztreonam and cefotaxime against Escherichia coli and Bacteroides spp. in pure and mixed cultures. Antimicrob Agents Chemother 1984; 26:39–41.Google Scholar
42. Mullaney, DT, John, JF: Cefotaxime therapy. Arch Intern Med 1983; 143:1705–1708.Google Scholar
43. DiPiro, JT, Record, KE, Bivins, BA: Evaluation of new cephalosporins for prophylaxis of surgical infection. Clin Pharm 1982; 1:135–140.Google Scholar
44. Nord, CE, Kager, L, Heimdahl, A: Impact of antimicrobial agents on the gastrointestinal microflora and the risk of infections. Am J Med 1984; 76(special issue):99–106.Google Scholar
45. Cunningham, FC, Hemsell, DL, DePalma, RT, et al: Moxalactam for obstetric and gynecologic infections. Am J Obstet Gynecol 1981; 139:915–921.CrossRefGoogle ScholarPubMed
46. Haverkos, HW, Caparosa, R, Yu, VL, et al: Moxalactam therapy. Arch Otolaryngol 1982; 108:329–333.Google Scholar
47. Overturf, CD, Cable, DC, Forthal, DN, et al: Treatment of bacterial meningitis with ceftizoxime. Antimicrob Agents Chemother 1984; 25:258–262.Google Scholar
48. Geelhoed, GW, Simon, GL: Systemic antibiotic therapy in surgical patients. South Med J 1984; 77:355–359.Google Scholar
49. Aronoff, GR, Brier, ME, Nierste, DM, et al: Interactions of moxalactam and tobramycin in normal volunteers and in patients with impaired renal function. J Infect Dis 1984; 149:9–15.Google Scholar
50. Moxalactam disodium (Moxam). Med Lett Drugs Ther 1982; 24:13–14.Google Scholar
51. Gorbach, SL: Treatment of intraabdominal infection. Am J Med 1984; 76(special issue): 107–110.Google Scholar
52. Pakter, RL, Russell, TR, Mielke, CH, et al: Coagulopathy associated with the use of moxalactam. JAMA 1982; 248:1100.CrossRefGoogle ScholarPubMed
53. Weitekamp, MR, Aber, RC: Prolonged bleeding times and bleeding diathesis associated with moxalactam administration. JAMA 1983; 249:69–71.CrossRefGoogle ScholarPubMed
54. Yu, VL: Enterococcal superinfection and colonization after therapy with moxalactam, a new broad spectrum antibiotic. Ann Intern Med 1981; 94:784–785.Google Scholar
55. Neu, HC, Prince, AS: Interaction between moxalactam and alcohol. Lancet 1980; 2:1422.CrossRefGoogle Scholar
56. File, TM, Tan, JS: Cefoperazone for the treatment of acute urinary tract infection: Multicentered comparative and noncomparative studies. Rev Infect Dts 1983; 5(suppl):S145–S153.CrossRefGoogle ScholarPubMed
57. Cefoperazone sodium (Cefobid). Med Lett Drugs Ther 1983; 25:29–30.Google Scholar
58. Carlberg, H, Alestig, K, Nord, CE, et al: Intestinal side effects of cefoperazone. J Antimicrob Chemother 1982; 10:483–487.CrossRefGoogle ScholarPubMed
59. Ebright, JR, Franson, TR, Moore, EC: Comparative trial of ceftizoxime and cefamandole in therapy of bacterial pneumonia. Current Therapeutic Research 1983; 33:39–45.Google Scholar
60. Scully, BE, Neu, HC: Clinical efficacy of ceftazidime. Arch Intern Med 1984; 144:57–62.Google Scholar
61. Rapp, RP, Young, B, Foster, TS, et al: Ceftazidime versus tobi amycin/ticarcillin in treating hospital acquired pneumonia and bacteremia. Pharmacotherapy 1984;4:211–215.CrossRefGoogle Scholar
62. Just, HM, Frank, U, Simon, A, et al: Concentrations of ceftriaxone in serum and lung tissue. Chemotherapy 1984; 30:81–83.CrossRefGoogle ScholarPubMed
63. Steele, RW, Bradsher, RW: Ceftriaxone for the treatment of serious infections. Am J Dis Child 1983; 137:1044–1047.Google Scholar
64. Baumgartner, J, Glauser, MP: Single daily dose treatment of severe refractory infections with ceftriaxone. Arch Intern Med 1983; 143:1868–1873.CrossRefGoogle ScholarPubMed